Literature DB >> 10502773

Overview of mutations in the PCCA and PCCB genes causing propionic acidemia.

M Ugarte1, C Pérez-Cerdá, P Rodríguez-Pombo, L R Desviat, B Pérez, E Richard, S Muro, E Campeau, T Ohura, R A Gravel.   

Abstract

Propionic acidemia is an inborn error of metabolism caused by a deficiency of propionyl-CoA carboxylase, a heteropolymeric mitochondrial enzyme involved in the catabolism of branched chain amino acids, odd-numbered chain length fatty acids, cholesterol, and other metabolites. The enzyme is composed of alpha and beta subunits which are encoded by the PCCA and PCCB genes, respectively. Mutations in both genes can cause propionic acidemia. The identification of the responsible gene, previous to mutation analysis, can be performed by complementation assay or, in some instances, can be deduced from peculiarities relevant to either gene, including obtaining normal enzyme activity in the parents of many patients with PCCB mutations, observing combined absence of alpha and beta subunits by Western blot of many PCCA patients, as well as conventional mRNA-minus result of Northern blots for either gene or beta subunit deficiency in PCCB patients. Mutations in both the PCCA and PCCB genes have been identified by sequencing either RT-PCR products or amplified exonic fragments, the latter specifically for the PCCB gene for which the genomic structure is available. To date, 24 mutations in the PCCA gene and 29 in the PCCB gene have been reported, most of them single base substitutions causing amino acid replacements and a variety of splicing defects. A greater heterogeneity is observed in the PCCA gene-no mutation is predominant in the populations studied-while for the PCCB gene, a limited number of mutations is responsible for the majority of the alleles characterized in both Caucasian and Oriental populations. These two populations show a different spectrum of mutations, only sharing some involving CpG dinucleotides, probably as recurrent mutational events. Future analysis of the mutations identified, of their functional effect and their clinical relevance, will reveal potential genotype-phenotype correlations for this clinically heterogeneous disorder. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502773     DOI: 10.1002/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  26 in total

1.  The molecular basis of 3-methylcrotonylglycinuria, a disorder of leucine catabolism.

Authors:  M E Gallardo; L R Desviat; J M Rodríguez; J Esparza-Gordillo; C Pérez-Cerdá; B Pérez; P Rodríguez-Pombo; O Criado; R Sanz; D H Morton; K M Gibson; T P Le; A Ribes; S R de Córdoba; M Ugarte; M A Peñalva
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

2.  Mutations affecting the beta-beta homomeric interaction in propionic acidaemia: an approach to the determination of the beta-propionyl-CoA carboxylase functional domains.

Authors:  S Muro; B Pérez; P Rodríguez-Pombo; L R Desviat; C Pérez-Cerdá; M Ugarte
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

3.  Mutation analysis in 54 propionic acidemia patients.

Authors:  J P Kraus; E Spector; S Venezia; P Estes; P W Chiang; G Creadon-Swindell; S Müllerleile; L de Silva; M Barth; M Walter; K Walter; T Meissner; M Lindner; R Ensenauer; R Santer; O A Bodamer; M R Baumgartner; M Brunner-Krainz; D Karall; C Haase; I Knerr; T Marquardt; J B Hennermann; R Steinfeld; S Beblo; H G Koch; V Konstantopoulou; S Scholl-Bürgi; A van Teeffelen-Heithoff; T Suormala; M Ugarte; W Sperl; A Superti-Furga; K O Schwab; S C Grünert; J O Sass
Journal:  J Inherit Metab Dis       Date:  2011-10-27       Impact factor: 4.982

4.  High incidence of propionic acidemia in greenland is due to a prevalent mutation, 1540insCCC, in the gene for the beta-subunit of propionyl CoA carboxylase.

Authors:  K Ravn; M Chloupkova; E Christensen; N J Brandt; H Simonsen; J P Kraus; I M Nielsen; F Skovby; M Schwartz
Journal:  Am J Hum Genet       Date:  2000-05-16       Impact factor: 11.025

5.  Nutritional and Pharmacological Management during Chemotherapy in a Patient with Propionic Acidaemia and Rhabdomyosarcoma Botryoides.

Authors:  E Martín-Hernández; P Quijada-Fraile; L Oliveros-Leal; Mt García-Silva; C Pérez-Cerdá; M Baro-Fernández; V Pérez-Alonso; Jl Vivanco
Journal:  JIMD Rep       Date:  2012-03-21

6.  Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes.

Authors:  M Sol Collado; Allison J Armstrong; Matthew Olson; Stephen A Hoang; Nathan Day; Marshall Summar; Kimberly A Chapman; John Reardon; Robert A Figler; Brian R Wamhoff
Journal:  Mol Genet Metab       Date:  2020-05-11       Impact factor: 4.797

7.  The molecular landscape of propionic acidemia and methylmalonic aciduria in Latin America.

Authors:  Belén Pérez; Celia Angaroni; Rocio Sánchez-Alcudia; Begoña Merinero; Celia Pérez-Cerdá; N Specola; P Rodríguez-Pombo; Moacir Wajner; Raquel Dodelson de Kremer; Verónica Cornejo; Lourdes R Desviat; Magdalena Ugarte
Journal:  J Inherit Metab Dis       Date:  2010-06-15       Impact factor: 4.982

8.  Recapitulation of metabolic defects in a model of propionic acidemia using patient-derived primary hepatocytes.

Authors:  Kimberly A Chapman; Maria S Collado; Robert A Figler; Stephen A Hoang; Allison J Armstrong; Wanxing Cui; Michael Purdy; Michael B Simmers; Nada A Yazigi; Marshall L Summar; Brian R Wamhoff; Ajit Dash
Journal:  Mol Genet Metab       Date:  2015-12-24       Impact factor: 4.797

Review 9.  Methylmalonic and propionic acidemias: clinical management update.

Authors:  Jamie L Fraser; Charles P Venditti
Journal:  Curr Opin Pediatr       Date:  2016-12       Impact factor: 2.856

10.  Analysis of common mutations in the galactose-1-phosphate uridyl transferase gene: new assays to increase the sensitivity and specificity of newborn screening for galactosemia.

Authors:  Steven F Dobrowolski; Richard A Banas; Joseph G Suzow; Michelle Berkley; Edwin W Naylor
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.